Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors (Q35713515)

9 August 2017

title

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors (English)

1 reference

9 August 2017

Masayuki Hijioka

1

1 reference

9 August 2017

Tetsuhide Ito

2

1 reference

9 August 2017

Hisato Igarashi

3

1 reference

9 August 2017

Nao Fujimori

4

1 reference

9 August 2017

Lingaku Lee

5

1 reference

9 August 2017

Taichi Nakamura

6

1 reference

9 August 2017

Robert T Jensen

7

1 reference

9 August 2017

Ryoichi Takayanagi

8

1 reference

9 August 2017

language of work or name

1 reference

18 October 2014

1 reference

9 August 2017

1 reference

9 August 2017

volume

105

1 reference

9 August 2017

issue

11

1 reference

9 August 2017

page(s)

1464-1471

1 reference

Current update on medullary thyroid carcinoma

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Zollinger-Ellison syndrome: recent advances and controversies

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Autoimmune pancreatitis associated with high levels of chromogranin a, serotonin and 5-hydroxyindoleacetic Acid

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Everolimus for advanced pancreatic neuroendocrine tumors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Gastroenteropancreatic neuroendocrine tumours

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Endocrine tumours of the pancreas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

The chromogranin-secretogranin family

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Ethnic differences in breast cancer risk: a possible role for pregnancy levels of alpha-fetoprotein?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Chromogranin A: its clinical value as marker of neuroendocrine tumours

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

The primary structure of human chromogranin A and pancreastatin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan

27 July 2018

1 reference

Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis

21 January 2018

1 reference

Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma

21 January 2018

1 reference

Autoimmune pancreatitis in Japan: overview and perspective

21 January 2018

1 reference

Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.

21 January 2018

1 reference

Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours

21 January 2018

1 reference

Diagnostic value of plasma chromogranin A in neuroendocrine tumours.

21 January 2018

1 reference

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours

21 January 2018

1 reference

Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors

21 January 2018

1 reference

Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours

21 January 2018

1 reference

Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role

21 January 2018

1 reference

Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors

21 January 2018

1 reference

Chromogranin a in physiology and oncology.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Chromogranin A: is it a useful marker of neuroendocrine tumors?

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462381

Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina

25 September 2018

1 reference

12 December 2020

Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects

1 reference

12 December 2020

The revised Japanese clinical diagnostic criteria for chronic pancreatitis

1 reference

12 December 2020

Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer

1 reference

12 December 2020

Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript

1 reference

12 December 2020

Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1

1 reference

12 December 2020

Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the α-Subunit of Glycoprotein Hormones

1 reference

12 December 2020

Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study

1 reference

12 December 2020

Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies

1 reference

12 December 2020

Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments

1 reference

12 December 2020

Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients

1 reference

12 December 2020

Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study

1 reference

12 December 2020

[Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood]

1 reference

12 December 2020

Identifiers

DOI

10.1111/CAS.12533

1 reference

9 August 2017

1 reference

9 August 2017

1 reference